Caribou Cost Of Revenue vs Ebitda Analysis

CRBU Stock

USD 2.37 0.18 8.22%

Caribou Biosciences financial indicator trend analysis is way more than just evaluating Caribou Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Caribou Biosciences is a good investment. Please check the relationship between Caribou Biosciences Cost Of Revenue and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caribou Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Caribou Biosciences Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Caribou Biosciences' Cost Of Revenue and Ebitda is -0.62. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Caribou Biosciences, assuming nothing else is changed. The correlation between historical values of Caribou Biosciences' Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Caribou Biosciences are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Caribou Biosciences' Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.62

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Caribou Biosciences income statement and represents the costs associated with goods and services Caribou Biosciences provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Caribou Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Caribou Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caribou Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.At this time, Caribou Biosciences' Tax Provision is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 730.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.9 M in 2024.

	2020	2021	2023	2024 (projected)
Interest Income	236K	148K	133.2K	126.5K
Net Interest Income	216K	140K	126K	119.7K

Interest Income Net Interest Income

Caribou Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.74	0.92	0.98	1.0	0.98	1.0	0.75	0.86	-0.46	-0.86	0.18	0.67	0.91	0.91	0.89	0.99	0.53	0.99	0.63	0.89	-0.8	-0.92	0.94	0.99	0.66
Short Long Term Debt Total	0.74		0.86	0.82	0.72	0.61	0.68	0.99	0.6	0.23	-0.95	-0.39	0.08	0.9	0.92	0.88	0.68	-0.08	0.76	0.79	0.93	-0.44	-0.93	0.76	0.8	0.94
Other Current Liab	0.92	0.86		0.95	0.91	0.86	0.9	0.87	0.67	-0.14	-0.95	0.07	0.38	0.93	0.96	0.96	0.87	0.29	0.95	0.82	0.93	-0.67	-0.94	0.9	0.97	0.77
Total Current Liabilities	0.98	0.82	0.95		0.98	0.95	0.97	0.82	0.86	-0.33	-0.91	0.03	0.56	0.96	0.95	0.93	0.96	0.47	0.99	0.66	0.92	-0.72	-0.97	0.97	0.99	0.78
Total Stockholder Equity	1.0	0.72	0.91	0.98		0.98	1.0	0.73	0.86	-0.48	-0.84	0.2	0.69	0.9	0.9	0.88	0.99	0.54	0.99	0.63	0.88	-0.81	-0.91	0.93	0.98	0.64
Other Liab	0.98	0.61	0.86	0.95	0.98		0.98	0.62	0.87	-0.6	-0.77	0.31	0.78	0.83	0.82	0.8	0.99	0.69	0.96	0.53	0.81	-0.84	-0.85	0.94	0.94	0.56
Net Tangible Assets	1.0	0.68	0.9	0.97	1.0	0.98		0.69	0.87	-0.52	-0.81	0.21	0.7	0.89	0.88	0.87	0.99	0.57	0.99	0.58	0.84	-0.79	-0.89	0.93	0.98	0.61
Property Plant And Equipment Net	0.75	0.99	0.87	0.82	0.73	0.62	0.69		0.57	0.21	-0.97	-0.33	0.11	0.88	0.91	0.87	0.69	-0.08	0.76	0.84	0.95	-0.5	-0.93	0.74	0.81	0.9
Current Deferred Revenue	0.86	0.6	0.67	0.86	0.86	0.87	0.87	0.57		-0.52	-0.64	-0.09	0.7	0.83	0.76	0.7	0.9	0.63	0.84	0.23	0.69	-0.6	-0.82	0.89	0.81	0.67
Net Debt	-0.46	0.23	-0.14	-0.33	-0.48	-0.6	-0.52	0.21	-0.52		0.0	-0.69	-0.94	-0.11	-0.06	-0.05	-0.54	-0.9	-0.39	0.17	-0.1	0.64	0.13	-0.37	-0.33	0.24
Retained Earnings	-0.86	-0.95	-0.95	-0.91	-0.84	-0.77	-0.81	-0.97	-0.64	0.0		0.1	-0.3	-0.9	-0.94	-0.9	-0.81	-0.14	-0.86	-0.87	-0.99	0.67	0.96	-0.85	-0.9	-0.84
Accounts Payable	0.18	-0.39	0.07	0.03	0.2	0.31	0.21	-0.33	-0.09	-0.69	0.1		0.58	-0.21	-0.16	-0.1	0.21	0.56	0.13	0.1	-0.05	-0.53	0.17	0.02	0.11	-0.55
Cash	0.67	0.08	0.38	0.56	0.69	0.78	0.7	0.11	0.7	-0.94	-0.3	0.58		0.35	0.31	0.27	0.74	0.89	0.59	0.08	0.4	-0.83	-0.41	0.59	0.55	0.04
Non Current Assets Total	0.91	0.9	0.93	0.96	0.9	0.83	0.89	0.88	0.83	-0.11	-0.9	-0.21	0.35		0.99	0.97	0.88	0.27	0.94	0.64	0.89	-0.52	-0.98	0.93	0.95	0.89
Non Currrent Assets Other	0.91	0.92	0.96	0.95	0.9	0.82	0.88	0.91	0.76	-0.06	-0.94	-0.16	0.31	0.99		0.99	0.87	0.19	0.94	0.74	0.92	-0.55	-0.98	0.89	0.95	0.87
Other Assets	0.89	0.88	0.96	0.93	0.88	0.8	0.87	0.87	0.7	-0.05	-0.9	-0.1	0.27	0.97	0.99		0.84	0.17	0.94	0.74	0.88	-0.51	-0.93	0.86	0.95	0.81
Cash And Short Term Investments	0.99	0.68	0.87	0.96	0.99	0.99	0.99	0.69	0.9	-0.54	-0.81	0.21	0.74	0.88	0.87	0.84		0.6	0.97	0.56	0.85	-0.82	-0.9	0.93	0.96	0.62
Net Receivables	0.53	-0.08	0.29	0.47	0.54	0.69	0.57	-0.08	0.63	-0.9	-0.14	0.56	0.89	0.27	0.19	0.17	0.6		0.48	-0.13	0.19	-0.59	-0.26	0.58	0.42	0.01
Common Stock Total Equity	0.99	0.76	0.95	0.99	0.99	0.96	0.99	0.76	0.84	-0.39	-0.86	0.13	0.59	0.94	0.94	0.94	0.97	0.48		0.65	0.88	-0.72	-0.93	0.94	1.0	0.7
Common Stock Shares Outstanding	0.63	0.79	0.82	0.66	0.63	0.53	0.58	0.84	0.23	0.17	-0.87	0.1	0.08	0.64	0.74	0.74	0.56	-0.13	0.65		0.85	-0.6	-0.72	0.54	0.71	0.56
Short Term Investments	0.89	0.93	0.93	0.92	0.88	0.81	0.84	0.95	0.69	-0.1	-0.99	-0.05	0.4	0.89	0.92	0.88	0.85	0.19	0.88	0.85		-0.75	-0.96	0.85	0.92	0.8
Non Current Liabilities Total	-0.8	-0.44	-0.67	-0.72	-0.81	-0.84	-0.79	-0.5	-0.6	0.64	0.67	-0.53	-0.83	-0.52	-0.55	-0.51	-0.82	-0.59	-0.72	-0.6	-0.75		0.65	-0.67	-0.74	-0.27
Inventory	-0.92	-0.93	-0.94	-0.97	-0.91	-0.85	-0.89	-0.93	-0.82	0.13	0.96	0.17	-0.41	-0.98	-0.98	-0.93	-0.9	-0.26	-0.93	-0.72	-0.96	0.65		-0.92	-0.95	-0.88
Other Current Assets	0.94	0.76	0.9	0.97	0.93	0.94	0.93	0.74	0.89	-0.37	-0.85	0.02	0.59	0.93	0.89	0.86	0.93	0.58	0.94	0.54	0.85	-0.67	-0.92		0.93	0.79
Other Stockholder Equity	0.99	0.8	0.97	0.99	0.98	0.94	0.98	0.81	0.81	-0.33	-0.9	0.11	0.55	0.95	0.95	0.95	0.96	0.42	1.0	0.71	0.92	-0.74	-0.95	0.93		0.72
Total Liab	0.66	0.94	0.77	0.78	0.64	0.56	0.61	0.9	0.67	0.24	-0.84	-0.55	0.04	0.89	0.87	0.81	0.62	0.01	0.7	0.56	0.8	-0.27	-0.88	0.79	0.72

Click cells to compare fundamentals

Caribou Biosciences Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Caribou Cost Of Revenue vs Ebitda Analysis

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Ebitda

Caribou Biosciences fundamental ratios Correlations

Caribou Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Caribou Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Total Assets

Short Term Investments	- 0.99	Retained Earnings
Inventory	- 0.98	Non Currrent Assets Other
Inventory	- 0.98	Non Current Assets Total
Retained Earnings	- 0.97	Property Plant And Equipment Net
Inventory	- 0.97	Total Current Liabilities
Inventory	- 0.96	Short Term Investments